NCT01974323View on ClinicalTrials.gov

Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

2,238

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Acne Vulgaris
Interventions
DRUG

Dapsone Gel

Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

DRUG

Dapsone Gel Vehicle

Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

Trial Locations (3)

Unknown

Beverly Hills

Aventura

Windsor

Sponsors

Lead Sponsor

Almirall, S.A.

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Almirall, S.A.

INDUSTRY

NCT01974323 - Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris | Biotech Hunter | Biotech Hunter